Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study.

Martina TallaricoCaterina PalleriaLivia RuffoloRocco Spagnuolo Maria Diana NaturaleAdele Emanuela De FrancescoCaterina De SarroRossella RomeoRita CitraroPatrizia DoldoLudovico AbenavoliLucia Muraca Francesco Luzza Antonio Leo Giovambattista De Sarro

Published in: Pharmaceutics (2022)

Based on the low rate of AEs observed and withdrawal from treatment, our data seem to corroborate the favorable beneficial/risk profile of biologics for IBDs.

Keyphrases

clinical practice
electronic health record
adverse drug
emergency department
combination therapy
drug induced
ulcerative colitis
replacement therapy